X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare GSK Pharma with Elder Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK PHARMA vs ELDER PHARMA - Comparison Results

GSK PHARMA    Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GSK PHARMA ELDER PHARMA GSK PHARMA/
ELDER PHARMA
 
P/E (TTM) x 64.5 -0.2 - View Chart
P/BV x 10.4 0.1 10,273.1% View Chart
Dividend Yield % 1.2 0.0 -  

Financials

 GSK PHARMA   ELDER PHARMA
EQUITY SHARE DATA
    GSK PHARMA
Mar-17
ELDER PHARMA
Jun-14
GSK PHARMA/
ELDER PHARMA
5-Yr Chart
Click to enlarge
High Rs3,838380 1,010.0%   
Low Rs2,637188 1,402.7%   
Sales per share (Unadj.) Rs354.2491.2 72.1%  
Earnings per share (Unadj.) Rs39.8-3.2 -1,249.8%  
Cash flow per share (Unadj.) Rs42.914.4 297.5%  
Dividends per share (Unadj.) Rs30.000-  
Dividend yield (eoy) %0.90-  
Book value per share (Unadj.) Rs236.9376.5 62.9%  
Shares outstanding (eoy) m84.7020.54 412.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x9.10.6 1,580.9%   
Avg P/E ratio x81.4-89.3 -91.2%  
P/CF ratio (eoy) x75.519.7 383.1%  
Price / Book Value ratio x13.70.8 1,811.5%  
Dividend payout %75.40-   
Avg Mkt Cap Rs m274,2165,833 4,700.8%   
No. of employees `0004.7NA-   
Total wages/salary Rs m4,8302,179 221.7%   
Avg. sales/employee Rs Th6,387.0NM-  
Avg. wages/employee Rs Th1,028.3NM-  
Avg. net profit/employee Rs Th717.1NM-  
INCOME DATA
Net Sales Rs m30,00010,089 297.4%  
Other income Rs m728257 283.8%   
Total revenues Rs m30,72810,346 297.0%   
Gross profit Rs m4,190-792 -529.1%  
Depreciation Rs m263361 72.8%   
Interest Rs m02,756 0.0%   
Profit before tax Rs m4,655-3,653 -127.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m4573,713 12.3%   
Tax Rs m1,744125 1,393.5%   
Profit after tax Rs m3,368-65 -5,153.8%  
Gross profit margin %14.0-7.8 -177.9%  
Effective tax rate %37.5-3.4 -1,093.5%   
Net profit margin %11.2-0.6 -1,733.2%  
BALANCE SHEET DATA
Current assets Rs m16,7429,240 181.2%   
Current liabilities Rs m7,2029,998 72.0%   
Net working cap to sales %31.8-7.5 -423.4%  
Current ratio x2.30.9 251.5%  
Inventory Days Days5246 111.9%  
Debtors Days Days2160 34.7%  
Net fixed assets Rs m8,63510,124 85.3%   
Share capital Rs m847206 411.8%   
"Free" reserves Rs m19,2225,582 344.3%   
Net worth Rs m20,0697,734 259.5%   
Long term debt Rs m104,889 0.2%   
Total assets Rs m30,03822,882 131.3%  
Interest coverage xNM-0.3-  
Debt to equity ratio x00.6 0.1%  
Sales to assets ratio x1.00.4 226.5%   
Return on assets %11.211.8 95.3%  
Return on equity %16.8-0.8 -1,986.0%  
Return on capital %25.522.3 114.1%  
Exports to sales %03.0 0.0%   
Imports to sales %00.4 0.0%   
Exports (fob) Rs mNA307 0.0%   
Imports (cif) Rs mNA43 0.0%   
Fx inflow Rs m528307 172.2%   
Fx outflow Rs m7,193125 5,740.6%   
Net fx Rs m-6,665181 -3,676.2%   
CASH FLOW
From Operations Rs m2,36011,754 20.1%  
From Investments Rs m3,008-561 -536.7%  
From Financial Activity Rs m-5,108-6,762 75.5%  
Net Cashflow Rs m2604,432 5.9%  

Share Holding

Indian Promoters % 0.0 39.6 -  
Foreign collaborators % 50.7 0.0 -  
Indian inst/Mut Fund % 10.2 7.5 136.0%  
FIIs % 23.8 16.8 141.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 15.4 36.1 42.7%  
Shareholders   102,036 16,479 619.2%  
Pledged promoter(s) holding % 0.0 77.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GSK PHARMA With:   TORRENT PHARMA  ALKEM LABORATORIES  DIVIS LABORATORIES  PFIZER  ALEMBIC PHARMA  

Compare GSK PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Of Sensex Touching New Highs, Takeaways from Acquisition of HPCL and Top Stocks in Action Today(Pre-Open)

BSE Sensex is on a roll. The index touched a record high of 35,798 yesterday. Considering a span of one year, the benchmark index has delivered a 32% return.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Mutual Funds Clearly Tell Us That There is a Bubble in the Stock Market(Vivek Kaul's Diary)

Jan 11, 2018

The maximum amount of money ever has come into equity mutual funds during the current financial year.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


Jan 22, 2018 (Close)

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

GSK PHARMA - PLETHICO PHARMA COMPARISON

COMPARE GSK PHARMA WITH

MARKET STATS